51116-01-9
51116-01-9 结构式
基本信息
8-BR-CGMP NA
8-BROMO-CGMP NA
Einecs 256-993-8
8-BROMO-CGMP SODIUM
8-BR-CGMP SODIUM SALT
(115974-70-4) 8-AET-cGMP
8-BROMO-CGMP, SODIUM SALT
8-bromo-Cyclic GMP (sodium salt)
8-BROMOGUANOSINE-3',5'-CYCLOPHOSPHATE SODIUM
常见问题列表
|
Ca 2+
|
8-Bromo-cGMP sodium (1-100 μM; 8 h) increases resistance of LLC-PK1 cells to CsA toxicity concentration-dependently.
8-Bromo-cGMP sodium (1-100 μM; 16 h) induces the synthesis of HO-1 protein in a concentration-dependent fashion.
Cell Viability Assay
| Cell Line: | LLC-PK1 cells (ATCC CL 101) |
| Concentration: | 1-100 μM |
| Incubation Time: | 8 hours |
| Result: | Increased resistance of LLC-PK1 cells to Cyclosporin A (CsA) toxicity concentration-dependently and augmented cell viability by up to 65%. |
Western Blot Analysis
| Cell Line: | LLC-PK1 cells (ATCC CL 101) |
| Concentration: | 1-100 μM |
| Incubation Time: | 16 hours |
| Result: | Induced the synthesis of HO-1 protein in a concentration-dependent fashion. |
8-Bromo-cGMP sodium (0.3, 1, 3.0 nmol; intrathecal administration; 10 min before test) dose-dependently and significantly increases the tail-flick latency in Vincristine-treated mice to the level observed in vehicle-treated naive mice (male ICR mice, 4weeks of age and weighing 20 g). Vincristine (0.05 mg/kg 1 day after the pre-drug tail-flick latency, and then 0.125 mg/kg twice a week for 6 weeks) can induce painful neuropathy in mice.
8-Bromo-cGMP sodium (10 mg/kg; iv; single dose) results in vasodilator responses in eNOS-Tg mice and WT littermates in C57BL/6 background (19-35 g).